Skip to main content
OpenTrials
Completed

NCT Number: NCT06655493

Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney Disease

This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease) with/without kidney disease.

The aim of the study is to assess the number of people with high levels of systemic inflammation among Middle East people with cardiovascular with/without kidney disease. Systemic inflammation means that it occurs throughout the body.

Participation in this study only requires a single visit at the clinic/hospital/medical institution. Participants will continue their normal care and will not get any treatment as part of this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Inflammation (hsCRP)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Almoosa Specialist Hospital, Al Ahsa, Saudi Arabia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • Male or female, age above or equal to 18 years at the time of signing informed consent.
  • Diagnosed with ASCVD+CKD and/or HF (pEF or mrEF)

Exclusion criteria

  • Previous participation in this study. Participation is defined as having given informed consent in this study.
  • Current participation (i.e., signed informed consent) in any other interventional clinical study.
  • Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization).
  • Clinical evidence, or suspicion of, active infection within the last 60 days.
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Treatment and study plan

No treatment given

Other

Participants will continue their normal care and will not get any treatment as part of this study.

Primary outcomes

  1. High Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L

    Time frame: At Visit (day 0)

    Count of patients

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

A Cross-sectional Study to Investigate Prevalence of Systemic Inflammation (hsCRP) in Cohort of Patients With HF and a Cohort of Patients With ASCVD and CKD in the Middle East

Acronym: INFLAMEAST

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Oct 23, 2024
Registry last updated
Oct 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.